Dean E. Brenner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dean E. Brenner has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Robert S. Bresalier
4 shared publicationsD.K. Turgeon
3 shared publications- Daniel Paul Normolle
Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania
3 shared publications - John A. Baron
Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 7936 One Medical Center Drive, Lebanon, NH 03756, USA
3 shared publications Norman E. Marcon
3 shared publicationsSapna Syngal
3 shared publications
Latest Publications
- Open Access
Cellular Pharmacology of Curcumin With and Without Piperine
Prior reports have suggested that piperine enhances curcumin’s anti-carcinogenesis. We tested the hypothesis that piperine increases the intracellular concentrations of curcumin by improving intracellular uptake or reducing curcumin efflux or metabolism in breast cells. We incubated SUM149, MCF10A, primary normal human breast cells, ALDH + , and ALDH - CD44 + 24 - SUM149 cells with curcumin ± piperine at concentrations 1 μM to 15 μM for time periods of 15 minutes to 24 hours. We assayed cell viability by MTT assay and proliferation by primary mammosphere assay. Curcumin and its metabolites were assayed using liquid chromatography mass spectroscopy. Curcumin, but not piperine, showed significantly higher effects on the viability of breast cancer SUM149 cells than in non-tumorigenic MCF10A cells. Curcumin + piperine synergistically reduced viability of SUM149 cells but had a concentration dependent effect upon MCF10A cell viability. Cellular uptake of curcumin in SUM149 is significantly higher, while the efflux in SUM149 is significantly lower than in MCF10A, which correlated with cell viability. Piperine did not alter curcumin cellular uptake, efflux, or metabolism in any of the cell models. The observed synergism of piperine+curcumin in reducing breast stem cell self renewal is likely due to independent anti-carcinogenesis effects rather than any effects upon intracellular curcumin concentrations.
Open AccessCellular Pharmacology of Curcumin With and Without Piperine
Prior reports have suggested that piperine enhances curcumin’s anti-carcinogenesis. We tested the hypothesis that piperine increases the intracellular concentrations of curcumin by improving intracellular uptake or reducing curcumin efflux or metabolism in breast cells. We incubated SUM149, MCF10A, primary normal human breast cells, ALDH + , and ALDH - CD44 + 24 - SUM149 cells with curcumin ± piperine at concentrations 1 μM to 15 μM for time periods of 15 minutes to 24 hours. We assayed cell viability by MTT assay and proliferation by primary mammosphere assay. Curcumin and its metabolites were assayed using liquid chromatography mass spectroscopy. Curcumin, but not piperine, showed significantly higher effects on the viability of breast cancer SUM149 cells than in non-tumorigenic MCF10A cells. Curcumin + piperine synergistically reduced viability of SUM149 cells but had a concentration dependent effect upon MCF10A cell viability. Cellular uptake of curcumin in SUM149 is significantly higher, while the efflux in SUM149 is significantly lower than in MCF10A, which correlated with cell viability. Piperine did not alter curcumin cellular uptake, efflux, or metabolism in any of the cell models. The observed synergism of piperine+curcumin in reducing breast stem cell self renewal is likely due to independent anti-carcinogenesis effects rather than any effects upon intracellular curcumin concentrations.
- 1 September 2019
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 71, 45-53
Dietary polyunsaturated fatty acids modulate adipose secretome and is associated with changes in mammary epithelial stem cell self-renewal
- 1 September 2019
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 71, 45-53
Dietary polyunsaturated fatty acids modulate adipose secretome and is associated with changes in mammary epithelial stem cell self-renewal
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1316
A Blood-Based Marker Panel for Detection of Colorectal Neoplasia
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1316
A Blood-Based Marker Panel for Detection of Colorectal Neoplasia
- 1 February 2013
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 6 (2) , 71-73
Trials and Tribulations of Interrogating Biomarkers to Define Efficacy of Cancer Risk Reductive Interventions
The challenges of clinical screening of cancer risk reductive interventions (“chemopreventive”) have slowed progress in deployment of therapeutics to reverse or delay the carcinogenesis process. The preoperative or window-of-opportunity design clinical trial design enrolls subjects rapidly, has short study periods, and quantifies tissue biomarkers that reflect both anti-carcinogenesis mechanism of the risk reductive intervention and key molecular events of the carcinogenesis process for a specific epithelial target. High subject screened to on study ratios reduce the efficiency and increase cost of this research strategy. Small-sized tissue samples obtained by minimally invasive endoscopic technologies limit the number of biomarkers that can be detected and quantified, forcing investigators into choosing either a broad-based but superficial multi-mechanism exploration of signaling intermediates or a more focused analysis of multiple molecular events in a linear signaling-specific pathway. More efficient strategies of the future might involve isolation and expansion of pluripotent cells from at-risk epithelium or intraepithelial neoplastic lesions. Such a strategy would allow interrogation of key carcinogenesis-associated pathways and mechanisms in representative primary single-cell cultures amenable to genomic, proteomics, or transfection-based technologies. Cancer Prev Res; 6(2); 71–3. ©2013 AACR.
- 1 February 2013
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 6 (2) , 71-73
Trials and Tribulations of Interrogating Biomarkers to Define Efficacy of Cancer Risk Reductive Interventions
The challenges of clinical screening of cancer risk reductive interventions (“chemopreventive”) have slowed progress in deployment of therapeutics to reverse or delay the carcinogenesis process. The preoperative or window-of-opportunity design clinical trial design enrolls subjects rapidly, has short study periods, and quantifies tissue biomarkers that reflect both anti-carcinogenesis mechanism of the risk reductive intervention and key molecular events of the carcinogenesis process for a specific epithelial target. High subject screened to on study ratios reduce the efficiency and increase cost of this research strategy. Small-sized tissue samples obtained by minimally invasive endoscopic technologies limit the number of biomarkers that can be detected and quantified, forcing investigators into choosing either a broad-based but superficial multi-mechanism exploration of signaling intermediates or a more focused analysis of multiple molecular events in a linear signaling-specific pathway. More efficient strategies of the future might involve isolation and expansion of pluripotent cells from at-risk epithelium or intraepithelial neoplastic lesions. Such a strategy would allow interrogation of key carcinogenesis-associated pathways and mechanisms in representative primary single-cell cultures amenable to genomic, proteomics, or transfection-based technologies. Cancer Prev Res; 6(2); 71–3. ©2013 AACR.
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
890 Sensitivity and Specificity of Fecal Immunochemical and Guaiac Testing for Occult Blood in Archived Frozen Stool Samples
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
890 Sensitivity and Specificity of Fecal Immunochemical and Guaiac Testing for Occult Blood in Archived Frozen Stool Samples
- Open Access
- 11 May 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 191
Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysis
Recent reports suggest increase in estrogen receptor (ER), progesterone receptor (PR) negative breast cancer yet little is known about histology or receptor status of breast cancer in Indian/Pakistani women.in the U.S.
- 11 May 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 191
Open AccessBreast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysis
Recent reports suggest increase in estrogen receptor (ER), progesterone receptor (PR) negative breast cancer yet little is known about histology or receptor status of breast cancer in Indian/Pakistani women.in the U.S.
- Top Cited PapersOpen Access
- 17 March 2006
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 6 (1) , 10
Dose escalation of a curcuminoid formulation
Background: Curcumin is the major yellow pigment extracted from turmeric, a commonly-used spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans have been performed.Methods: A dose escalation study was conducted to determine the maximum tolerated dose and safety of a single dose of standardized powder extract, uniformly milled curcumin (C3Complex™, Sabinsa Corporation). Healthy volunteers were administered escalating doses from 500 to 12,000 mg.Results: Seven of twenty-four subjects (30%) experienced only minimal toxicity that did not appear to be dose-related. No curcumin was detected in the serum of subjects administered 500, 1,000, 2,000, 4,000, 6,000 or 8,000 mg. Low levels of curcumin were detected in two subjects administered 10,000 or 12,000 mg.Conclusion: The tolerance of curcumin in high single oral doses appears to be excellent. Given that achieving systemic bioavailability of curcumin or its metabolites may not be essential for colorectal cancer chemoprevention, these findings warrant further investigation for its utility as a long-term chemopreventive agent.
- 17 March 2006
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 6 (1) , 10
Top Cited PapersOpen AccessDose escalation of a curcuminoid formulation
Background: Curcumin is the major yellow pigment extracted from turmeric, a commonly-used spice in India and Southeast Asia that has broad anticarcinogenic and cancer chemopreventive potential. However, few systematic studies of curcumin's pharmacology and toxicology in humans have been performed.Methods: A dose escalation study was conducted to determine the maximum tolerated dose and safety of a single dose of standardized powder extract, uniformly milled curcumin (C3Complex™, Sabinsa Corporation). Healthy volunteers were administered escalating doses from 500 to 12,000 mg.Results: Seven of twenty-four subjects (30%) experienced only minimal toxicity that did not appear to be dose-related. No curcumin was detected in the serum of subjects administered 500, 1,000, 2,000, 4,000, 6,000 or 8,000 mg. Low levels of curcumin were detected in two subjects administered 10,000 or 12,000 mg.Conclusion: The tolerance of curcumin in high single oral doses appears to be excellent. Given that achieving systemic bioavailability of curcumin or its metabolites may not be essential for colorectal cancer chemoprevention, these findings warrant further investigation for its utility as a long-term chemopreventive agent.
- Open Access
- 6 September 2005
- Published by Springer Nature in British Journal of Cancer
- Vol. 93 (7) , 735-739
Cancer chemoprevention: lessons learned and future directions
The concept of delaying or preventing epithelial transformation remains a viable and attainable goal for the future. Drug-based strategies for chemoprevention of the future may predominantly rely upon targeted therapies with tolerable but defined toxicities for treatment of individuals diagnosed with intraepithelial neoplasias. Foods, diet manipulation strategies, or nutraceuticals may be more appropriate to delay or prevent carcinogenesis progression in healthy populations with genetic or epidemiologic evidence of risk for future transformation.
- 6 September 2005
- Published by Springer Nature in British Journal of Cancer
- Vol. 93 (7) , 735-739
Open AccessCancer chemoprevention: lessons learned and future directions
The concept of delaying or preventing epithelial transformation remains a viable and attainable goal for the future. Drug-based strategies for chemoprevention of the future may predominantly rely upon targeted therapies with tolerable but defined toxicities for treatment of individuals diagnosed with intraepithelial neoplasias. Foods, diet manipulation strategies, or nutraceuticals may be more appropriate to delay or prevent carcinogenesis progression in healthy populations with genetic or epidemiologic evidence of risk for future transformation.